Cytori Therapeutics is set to gain cancer drugs and a liposomal nanoparticle technology platform through the acquisition of Azaya Therapeutics. The lead drug is a formulation of doxorubicin, the ...

Cytori Therapeutics said today it plans to acquire the liposomal nanoparticle technology platform of Azaya Therapeutics for up to $170 million, in a deal designed to expand and complement the buyer’s ...

Your Goa holidays have just gotten better. There’s a new ultra-luxe resort right on the pristine white sands of Benaulim beach with an unparalleled view of the Goa shoreline you must experience on ...

Azaya Therapeutics is conducting a study of a generic version of a popular drug used to treat ovarian cancer. The company hopes that drug will fill a gap in the market next year. Azaya’s drug is ...

The acquisition of two partner-ready nanoparticle cancer candidates developed by Azaya Therapeutics Inc. and an associated nanotech platform could yield potential near-term revenue for Cytori ...

Azaya Therapeutics Inc., a clinical-stage oncology company, has entered into an exclusive licensing agreement with CANbridge Life Sciences, which will develop and commercialize the San Antonio-based ...

Cytori Therapeutics Inc. stock surged 7.9% to $1.78 per share in morning trade Thursday after the company said it had agreed to purchase assets from privately-held Azaya Therapeutics. Under the terms ...

Parexo Labs, a division of Azaya, launches as a new CDMO with an emphasis on nanotechnology and liposomal manufacturing. Azaya Therapeutics, a biopharmaceutical company focused on focused on ...

SAN ANTONIO The National Cancer Institute has selected Azaya Therapeutics for a collaboration study of the company’s lead investigational cancer therapy, Azaya announced Monday. The studies, to be ...